317 Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients with Persistent High Triglycerides, EGFR <90 Ml/Min/1.73 M^2, and Elevated Highsensitivity C-Reactive Protein ≥2.0 Mg/L